ALPN Alpine Immune Sciences

Nivalis Therapeutics Inc a pharmaceutical company, focuses on the discovery and development of product candidates for patients with cystic fibrosis. Geographically operation of the group is functioned through United States.

$8.61  +0.10 (1.18%)
As of 07/01/2022 16:00:00 EST     IEX book   CBOE book


Security Information
Category1:  US Equity
Category2:  Common stocks
Category3:  Micro cap
GICS sector:  Health Care
Industry:  Biotechnology
Index country:  USA
Country of incorporation:  USA
IPO date:  06/17/2015
Outstanding shares:  30,328,462
Average volume:  133,224
Market cap:   $258,095,212
Current dividend yield:  0.00%
All SEC filings:     SEC Edgar Online
Quarterly filings:   10-Q
Annual filings:      10-K
Sedol:      BYX38M1
Valuation   (See tab for details)
PE ratio:   -5.53
PB ratio:   2.26
PS ratio:   10.18
Return on equity:   -40.91%
Net income %:   -186.25%

2022 © Stock Market MBA, Inc. Terms of use | Privacy policy